Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Adequate water intake becomes a deliberate habit rather than an intuitive one
SURMOUNT-5 was a phase 3b, open-label, controlled trial in 751 adults with obesity but without type 2 diabetes, randomized 1:1 to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg), once weekly for 72 weeks
Gastrointestinal effects like constipation or loose stools may develop slightly later, typically between day 2 and day 5 of treatment
This may increase the likelihood of digestive side effects or metabolic complications without improving results
Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: A multidisciplinary expert consensus
US$ 29.37
US$ 26.79
US$ 24.77
US$ 20.01
US$ 23.59
